Benefit-risk assessments are made by various stakeholders including sponsors, regulators, payers, physicians, and patients throughout the life-cycle of a treatment.
The understanding of data plays a vital role in weighing the positive and negative effects of medications.
In this episode, we give you an introduction to what benefit-risk (BR) assessment is for you to understand your role.
We also cover the following topics:
- What are the different situations, where BR becomes important?
- What is the difference between qualitative and quantitative BR assessments?
- Which relevant parties work on this topic?
- What are good resources to get started with BR and how will they help?
- What would you recommend as further readings and how can I get additional training?
- What is the BR SIG doing and how to become a member?
References
Featured courses
Click on the button to see our Teachble Inc. cources.
Maria Costa
Senior Director of Statistics in Therapeutic Vaccines (GSK)
Dr Maria Costa completed her PhD in Statistics at Warwick University in 2008 where she worked on developing new approaches for generalized additive and survival models using penalized spline functions. Dr Costa then became a Research Fellow at the Warwick Systems Biology Centre working on the connection between the circadian clock of plants and global warming as part of the ROBuST project.
Dr Costa has worked in the pharmaceutical industry since 2013, starting at GlaxoSmithKline R&D where she focused on developing methodology for quantitative Benefit-Risk assessment, as well as providing statistical consultancy on complex clinical trial designs to multiple projects across R&D. Since 2018 Dr Costa has joined Novartis Pharma as an Associate Director in Biostatistics.
Dr Costa is interested in the fields of benefit-risk assessment, Bayesian inference, adaptive designs, and probability of success.
Shahrul Mt-Isa
Dr Shahrul Mt-Isa is a Principal Scientist in the Health Technology Assessment (HTA) Statistics research group under the MSD Research Laboratories (MRL) Biostatistics and Research Decision Sciences (BARDS) organization. He is responsible for statistical analyses in clinical study portfolios in antiviral, antibacterial, and oncology indications to support HTA dossier submissions globally.
He co-leads the MRL Benefit-Risk (BR) Strategic Initiative to innovate and implement novel methodologies and processes for BR Assessment. Externally, he is an active member of the EFPSI BR and HTA Special Interest Groups.
Before joining MSD, he was the Deputy Public Lead in the IMI-PROTECT BR Work Package (WP5) while serving as an academic statistician at the School of Public Health, Imperial College London, where he currently holds an Honorary Fellowship.
Join The Effective Statistician LinkedIn group
This group was set up to help each other to become more effective statisticians. We’ll run challenges in this group, e.g. around writing abstracts for conferences or other projects. I’ll also post into this group further content.
I want to help the community of statisticians, data scientists, programmers and other quantitative scientists to be more influential, innovative, and effective. I believe that as a community we can help our research, our regulatory and payer systems, and ultimately physicians and patients take better decisions based on better evidence.
I work to achieve a future in which everyone can access the right evidence in the right format at the right time to make sound decisions.
When my kids are sick, I want to have good evidence to discuss with the physician about the different therapy choices.
When my mother is sick, I want her to understand the evidence and being able to understand it.
When I get sick, I want to find evidence that I can trust and that helps me to have meaningful discussions with my healthcare professionals.
I want to live in a world, where the media reports correctly about medical evidence and in which society distinguishes between fake evidence and real evidence.
Let’s work together to achieve this.
